Skip to main content

What the FDA labels say about taking them together

Cyclosporine and norethindrone

Norethindrone's FDA label of January 31, 2026 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name norethindrone. The norethindrone label: “Consequently, systemic concentrations may either increase or decrease.”

Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the norethindrone FDA label on DailyMed (effective January 31, 2026, Glenmark Pharmaceuticals Inc., USA).

What does the cyclosporine label say about norethindrone?

Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name norethindrone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed

What does the norethindrone label say about cyclosporine?

Norethindrone label, drug interactions

Consequently, systemic concentrations may either increase (for example, cyclosporine) or decrease.

Source: FDA drug label (Norethindrone), Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026 (SPL set 0d2f8fea-3675-40d2-afd9-9fcb148dbd4b), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Cyclosporine generic labelers
18Norethindrone generic labelers
CyclosporineNorethindrone
Labeled forOrgan transplant rejection, Rheumatoid arthritisBirth control
Boxed warningYesNo
Pharmacy cost (NADAC)$1.04 per unit 0.05% eye emulsion$0.290 per tablet 5 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?